ES2202855T3 - USE OF 5HT3 ANTAGONISTS TO PROMOTE INTESTINAL WASHING. - Google Patents

USE OF 5HT3 ANTAGONISTS TO PROMOTE INTESTINAL WASHING.

Info

Publication number
ES2202855T3
ES2202855T3 ES98922759T ES98922759T ES2202855T3 ES 2202855 T3 ES2202855 T3 ES 2202855T3 ES 98922759 T ES98922759 T ES 98922759T ES 98922759 T ES98922759 T ES 98922759T ES 2202855 T3 ES2202855 T3 ES 2202855T3
Authority
ES
Spain
Prior art keywords
antagonists
promote intestinal
intestinal washing
washing
promote
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98922759T
Other languages
Spanish (es)
Inventor
Antonius Adrianus Hendr Megens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of ES2202855T3 publication Critical patent/ES2202855T3/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention is concerned with the use of 5HT3 antagonists for promoting intestinal lavage, especially in combination with an osmotic agent.
ES98922759T 1997-04-18 1998-04-14 USE OF 5HT3 ANTAGONISTS TO PROMOTE INTESTINAL WASHING. Expired - Lifetime ES2202855T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97201149 1997-04-18

Publications (1)

Publication Number Publication Date
ES2202855T3 true ES2202855T3 (en) 2004-04-01

Family

ID=8228223

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98922759T Expired - Lifetime ES2202855T3 (en) 1997-04-18 1998-04-14 USE OF 5HT3 ANTAGONISTS TO PROMOTE INTESTINAL WASHING.

Country Status (12)

Country Link
US (2) US6235745B1 (en)
EP (1) EP0975327B1 (en)
JP (1) JP2001523239A (en)
KR (1) KR100529512B1 (en)
AT (1) ATE243993T1 (en)
AU (1) AU745361B2 (en)
CA (1) CA2286076C (en)
DE (1) DE69816060T2 (en)
DK (1) DK0975327T3 (en)
ES (1) ES2202855T3 (en)
PT (1) PT975327E (en)
WO (1) WO1998047481A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1090638A1 (en) * 1999-10-08 2001-04-11 Sanofi-Synthelabo Use of (R)-zacopride or a salt thereof for the manufacture of a medicament for the treatment of sleep apnea
AU2002231627A1 (en) * 2000-11-24 2002-06-03 Janssen Pharmaceutica N.V. Use of a triple combination comprising a 5HT3 antagonist, a 5HT4 agonist and a laxative for promoting intestinal lavage
PE20021019A1 (en) 2001-04-19 2002-11-13 Upjohn Co SUBSTITUTED AZABYCLE GROUPS
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
TWI332943B (en) * 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
RU2229882C2 (en) * 2002-04-05 2004-06-10 Научно-производственный центр "Фармзащита" Medicinal agent
US6946149B2 (en) * 2002-04-30 2005-09-20 Braintree Laboratories, Inc. Salt solution for colon cleansing
AU2003272740A1 (en) * 2002-10-01 2004-04-23 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 4,6-diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors
US6996500B2 (en) * 2002-10-30 2006-02-07 Hewlett-Packard Development Company, L.P. Method for communicating diagnostic data
BRPI0406749A (en) * 2003-01-13 2005-12-20 Dynogen Pharmaceuticals Inc Methods related to treatment of bowel dysfunction and pharmaceutical composition
AU2004204827B2 (en) * 2003-01-13 2006-06-29 Dynogen Pharmaceuticals, Inc. Method of treating nausea, vomiting, retching or any combination thereof
ATE365554T1 (en) * 2003-04-04 2007-07-15 Dynogen Pharmaceuticals Inc METHOD OF TREATING LOWER URINARY TRACT DISEASES
US7049319B2 (en) * 2003-09-23 2006-05-23 Semaan Abboud Colon cleansing composition and method
JPWO2005099698A1 (en) * 2004-04-15 2008-03-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 Stabilized 4-amino-5-chloro-N-[(1R, 3r, 5S) -8-methyl-8-azabicyclo [3.2.1] oct-3-yl] -2- [1-methylbuta -2-Inyloxy] benzamide-containing composition
WO2006105117A2 (en) * 2005-03-28 2006-10-05 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
WO2007019888A2 (en) * 2005-08-12 2007-02-22 Ctg Pharma S.R.L. Therapeutic compositions containing mesalamine and a co-agent for treating colon diseases
WO2007021881A1 (en) * 2005-08-16 2007-02-22 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amide) formulation
JP2009506069A (en) * 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド Neurogenesis through modulation of muscarinic receptors
CN101528225B (en) * 2006-08-07 2013-07-17 阿尔巴尼分子研究公司 2-aminobenzoxazole carboxamides as 5HT3 modulators
US7553846B2 (en) 2006-08-07 2009-06-30 Albany Molecular Research, Inc. 2-alkylbenzoxazole carboxamides as 5-HT3 modulators
EP3718557A3 (en) * 2013-02-25 2020-10-21 Bausch Health Ireland Limited Guanylate cyclase receptor agonist sp-333 for use in colonic cleansing
CA2903283C (en) 2013-03-15 2023-09-05 Braintree Laboratories, Inc. Dual use oral pharmaceutical composition tablets of sulfate salts and methods of use thereof
US10172833B2 (en) 2015-08-11 2019-01-08 Insys Development Company, Inc. Sublingual ondansetron spray
US10143656B1 (en) 2017-08-04 2018-12-04 Braintree Laboratories, Inc. Solid oral sulfate salt formulations for cleaning a colon and methods of using same
JP7443238B2 (en) * 2018-09-28 2024-03-05 武田薬品工業株式会社 heterocyclic compound
US12239659B2 (en) 2023-06-15 2025-03-04 Braintree Laboratories, Inc. Methods of administering safe colon cleansing compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB893267A (en) * 1958-11-25 1962-04-04 Sterling Drug Inc Laxative enemas
US5166145A (en) * 1990-09-10 1992-11-24 Alza Corporation Antiemetic therapy
TW294595B (en) * 1992-11-20 1997-01-01 Janssen Pharmaceutica Nv
US6103734A (en) 1994-11-04 2000-08-15 Legarda Ibanez; Juan Jose Drug combination as a medicament to suppress the dependence of individuals to opiates
WO1996014071A1 (en) * 1994-11-04 1996-05-17 Legarda Ibanez Juan Jose Combination of chemical compounds used as a medicament intended to suppress the dependence of individuals to opioids
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis

Also Published As

Publication number Publication date
CA2286076A1 (en) 1998-10-29
EP0975327B1 (en) 2003-07-02
US20010020025A1 (en) 2001-09-06
CA2286076C (en) 2006-12-12
AU7528298A (en) 1998-11-13
US6235745B1 (en) 2001-05-22
ATE243993T1 (en) 2003-07-15
KR100529512B1 (en) 2005-11-22
JP2001523239A (en) 2001-11-20
WO1998047481A1 (en) 1998-10-29
PT975327E (en) 2003-11-28
KR20000075858A (en) 2000-12-26
DE69816060D1 (en) 2003-08-07
EP0975327A1 (en) 2000-02-02
DK0975327T3 (en) 2003-10-20
AU745361B2 (en) 2002-03-21
US6555546B2 (en) 2003-04-29
DE69816060T2 (en) 2004-04-22

Similar Documents

Publication Publication Date Title
PT975327E (en) USE OF 5HT3 ANTAGONISTS TO STIMULATE INTESTINAL WASHING
TR200000782T2 (en) Resorcinol derivatives.
MXPA03001511A (en) IMIDAZOL-5-IL-2-AMINO-PYRIMIDINS AS AGENTS FOR THE INHIBITION OF THE CELL PROLIFERATION.
MX9705296A (en) Novel compounds.
ES2195970T3 (en) L-RIBAVIRINA AND USES OF THE SAME.
DE69819311D1 (en) NEW BENZIMIDAZOL INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE
DK0880523T3 (en) Pyrazolopyrimidines as CRF receptor antagonists
EA200100773A1 (en) SUBSTITUTED 1-HETEROCYCLIC DIARYLAMINES
ES2157027T3 (en) OXAZOLIDINONES REPLACED AND ITS USE AS ANTIBACTERIAL PHARMACOS.
BR0107246A (en) Diazabicyclic agents active in the central nervous system
BR0113798A (en) Resorcinol Derivatives
NO993350L (en) Vitronectin receptor antagonists
AR016981A2 (en) SYNTHETIC POLYPEPTIDES
BR0007864A (en) Compound, and, use of a compound
EA200300593A1 (en) PIPERASINYLPIRASIN COMPOUNDS AS AGONISTS OR ANTAGONISTS OF SEROTONIN 5-HT2 RECEPTOR
ES2190487T3 (en) NEW AGONISTS AND ANTAGONISTS OF THE ADENOSINE RECEIVER A1.
AR028162A1 (en) CONTROLLED AVAILABILITY OF FORMULATION COMPOUNDS, COMPOSITIONS AND WASHING METHODS USING THE SAME.
AR027846A1 (en) STABLE FORMULATION COMPONENTS, COMPOSITIONS AND WASHING METHODS USING THE SAME
BR9909486A (en) Calcilic compounds
UY27203A1 (en) USEFUL BENCIMIDAZOLS IN THE TREATMENT OF SEXUAL DYSFUNCTION
ECSP034531A (en) SUBSTITUTED DERIVATIVES OF C-CICLOHEXILMETILAMINA
TR200102742T2 (en) Resorcinol derivatives
ES2193197T3 (en) CATALITIC CRAQUIZATION COM MCM-49.
BR9807888B1 (en) liquid soaps as well as use of triclocarban.
IT1270612B (en) MORPHINOID HETEROCYCLE-CONDENSER DERIVATIVES